SGRY
Surgery Partners, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
14.53
▲ 0.59 (4.23%)
MARKET · —
Price
Open
14.29
Prev close
13.94
Day high
14.55
Day low
13.80
Volume
3.88M
Market cap
$1.90B
P/E (TTM)
—
52W range
11.41 – 23.66
Trailing performance
Returnvs SPY
1W
-3.39%
-2.0%
1M
-4.60%
-8.3%
3M
+9.30%
+6.2%
6M
-6.56%
-17.6%
YTD
-6.02%
-18.3%
1Y
-39.09%
-59.1%
3Y
-55.28%
-129.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.90B
Enterprise value$7.53B
Revenue (TTM)$3.37B
Gross profit$757.90M
EBITDA$646.40M
Net income$-88.60M
EPS (TTM)$-0.69
Free cash flow$183.56M
Total cash$216.70M
Total debt$4.07B
Book value / share$12.88
Shares outstanding130.92M
Float65.50M
Short % of float20.50%
Dividend yield—
Beta (5Y)1.94
Valuation & profitability ratios
Trailing P/E—
Forward P/E23.15
PEG ratio—
Price / sales—
Price / book1.13
EV / revenue2.24
EV / EBITDA11.65
Gross margin22.51%
Operating margin13.72%
Profit margin-2.63%
Return on equity2.32%
Return on assets3.67%
Debt / equity117.26
Current ratio1.95
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $3.31B | $3.11B | $2.74B | $2.54B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$77.90M | -$168.10M | -$11.90M | -$54.60M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$77.90M | -$168.10M | -$11.90M | -$54.60M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.06 | 0.10 | +59.6% |
| Mar 2026 | -0.14 | -0.03 | +77.8% |
| Dec 2025 | 0.30 | 0.12 | -59.7% |
| Sep 2025 | 0.16 | 0.13 | -19.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.13 | 10 | $854.75M | +4.1% |
| Next quarter | 0.30 | 10 | $906.72M | +2.5% |
| Current year | 0.48 | 11 | $3.42B | +3.3% |
| Next year | 0.62 | 11 | $3.52B | +3.1% |
Analyst targets & ownership
Mean target$18.73
High target$24.00
Low target$14.00
Implied upside28.89%
Analyst count11
ConsensusBUY
Strong buy / Buy1 / 8
Hold3
Sell / Strong sell0 / 0
Held by insiders1.80%
Held by institutions121.76%
Institutions holding265
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+716.19K
Net buying
Buy transactions
16
813.09K shares
Sell transactions
11
96.90K shares
Net transactions
+27
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
2.33M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | DELUCA TERESA Director |
BUY | 10.00K | $143.50K | Direct |
| Jun 18, 26 | HENDRIX BLAIR E Director |
STOCK | 34.36K | $500.00K | Direct |
| Jun 5, 26 | DELUCA TERESA Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | DEANE JOHN A Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | ADLERZ CLIFFORD G Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | HENDRIX BLAIR E Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | TURNER BRENT Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | DEAN LLOYD H Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | FORESE LAURA L Director |
STOCK | 11.67K | $160.00K | Direct |
| Mar 16, 26 | DOHERTY DAVID T. Chief Financial Officer |
SELL | 8.87K | $110.84K | Direct |
| Mar 16, 26 | EVANS JASON ERIC Chief Executive Officer |
SELL | 20.40K | $254.39K | Direct |
| Mar 13, 26 | BRITTENHAM MARISSA Officer |
SELL | 3.66K | $45.86K | Direct |
| Mar 13, 26 | BURKHALTER DANIELLE Officer |
SELL | 3.47K | $44.51K | Direct |
| Mar 12, 26 | BALDOCK JENNIFER BOYD Officer |
SELL | 5.80K | $76.36K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BALDOCK JENNIFER BOYD |
Officer | 326.47K | Sale |
BANE HARRISON R |
Officer | 117.18K | Sale |
BRITTENHAM MARISSA |
Officer | 94.20K | Sale |
BURKHALTER DANIELLE |
Officer | 76.86K | Sale |
DEVEYDT WAYNE S |
Officer and Director | 105.20K | Stock Award(Grant) |
DOHERTY DAVID T. |
Chief Financial Officer | 221.68K | Sale |
EVANS JASON ERIC |
Chief Executive Officer | 920.39K | Sale |
OPPENHEIMER JUSTIN ROBERT |
Chief Operating Officer | 120.26K | Stock Award(Grant) |
TURNER BRENT |
Director | 86.59K | Stock Award(Grant) |
WEBB WILLIAM TRENTON |
Officer | 104.35K | Sale |
Moving averages & technicals
SMA 10
14.71
-1.26% from price
SMA 20
15.15
-4.19% from price
SMA 50
15.54
-6.57% from price
SMA 100
14.61
-0.57% from price
SMA 200
14.95
-2.89% from price
EMA 12
14.68
-1.04% from price
EMA 26
15.07
-3.61% from price
EMA 50
15.13
-3.96% from price
RSI (14)
45.2
Neutral
MACD (12,26,9)
-0.39
Hist -0.15
ATR (14)
0.87
5.98% of price
Realised vol 30D
57.8%
Annualised
Bollinger upper
16.58
20, 2σ
Bollinger lower
13.73
20, 2σ
50 / 200 cross
Golden
15.54 vs 14.95
Trend bias
Below 200
-2.89%
Risk profile
Beta vs SPY
0.73
Less volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
57.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-51.4%
Peak to trough
Max drawdown 5Y
-81.4%
Peak to trough
ATR 14
0.87
5.98% of price
Beta (reported)
1.94
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.64
Call-heavy session
Put / call open interest
0.14
Positioning, not flow
Max pain
12.50
-13.9% from spot
ATM implied vol
53.3%
Nearest strike to spot
Skew (10% OTM)
+4.3%
Puts bid over calls
Call volume
155
Contracts, this expiry
Put volume
99
Contracts, this expiry
Heaviest call OI
17.50
2.15K contracts
Heaviest put OI
10.00
245 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Surgery Partners (SGRY) Stock May Be Undervalued After Q2 Earnings Beat
Simply Wall St. · 3d ago
Surgery Partners (SGRY) Q2 2026 Earnings Call Transcript
Motley Fool · 5d ago
The Top 5 Analyst Questions From Surgery Partners’s Q2 Earnings Call
StockStory · 5d ago
1 of Wall Street’s Favorite Stocks to Research Further and 2 We Avoid
StockStory · 6d ago
Outpatient & Specialty Care Stocks Q2 Highlights: Surgery Partners (NASDAQ:SGRY)
StockStory · 7d ago
SGRY Q2 Deep Dive: Portfolio Optimization and Acuity Mix Lead Operating Shift
StockStory · 9d ago
Surgery Partners (SGRY) Q2 Earnings: What To Expect
StockStory · 11d ago
RBC Capital Adjusts Price Target on Surgery Partners to $19 From $20, Keeps Outperform Rating
MT Newswires · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.